• VolitionRx Limited to Attend Conferences in December

  • Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies

  • VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update

  • VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update

  • VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits

  • VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding

  • VolitionRx Announces its European Colorectal Cancer Strategy

  • VolitionRx to Attend Two Major Conferences in Asia

  • Volition Granted Four Additional Patents

  • VolitionRx Limited to Attend Multiple Conferences in September

  • Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers

  • VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update

  • VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update

  • VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute

  • Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute

  • Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress

  • VolitionRx Limited Corrects an Earlier Announcement

  • VolitionRx Limited to Present at Multiple Investor Conferences in June

  • A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays

  • VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update

  • VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update

  • Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe

  • Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory

  • VolitionRx Appoints David Vanston as Chief Financial Officer

  • Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States

  • VolitionRx Limited Announces the Formation of Volition America, Inc.

  • VolitionRx Limited Celebrates CE Mark Announcement By Ringing Closing Bell at the New York Stock Exchange

  • VolitionRx Limited to Ring the New York Stock Exchange Closing Bell on Monday, March 13th at 4 pm Eastern Daylight Time

  • VolitionRx Limited Announces Full Fiscal Year 2016 Financial Results and Business Update

  • VolitionRx Limited to Present at the 29th Annual ROTH Conference

  • VolitionRx Limited Schedules Fourth Quarter and Full Year 2016 Earnings Conference Call and Business Update

  • A Logistics and Pathway Design Study for Volition's CE Marked NuQ(TM) Triage Test has been Commenced in the Capital Region of Denmark

  • VolitionRx Limited's Triage Test Results Validated in Prospective Trial

  • VolitionRx Limited to Attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference

  • VolitionRx Limited to Present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference on February 15, 2017

  • VolitionRx Limited Strengthens Team with Key Appointment to Drive Sales and Trials in Asia

  • VolitionRx Limited's Novel Cancer Diagnostic Test Achieves CE Marking as it Prepares for Launch Across Europe

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus